Last reviewed · How we verify
TAK-625
TAK-625 is a glucagon-like peptide-1 (GLP-1) receptor agonist.
TAK-625 is a glucagon-like peptide-1 (GLP-1) receptor agonist. Used for Type 2 diabetes.
At a glance
| Generic name | TAK-625 |
|---|---|
| Also known as | Maralixibat chloride |
| Sponsor | Takeda |
| Drug class | GLP-1 receptor agonist |
| Target | GLP-1R |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
TAK-625 works by mimicking the action of the natural hormone GLP-1, which helps to lower blood sugar levels by enhancing glucose-dependent insulin secretion, suppressing inappropriately elevated glucagon secretion, and slowing gastric emptying.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Diarrhea
- Abdominal pain
Key clinical trials
- A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
- A Study of TAK-625 for the Treatment of Alagille Syndrome (ALGS) (PHASE3)
- A Study of TAK-625 for the Treatment of Progressive Familial Intrahepatic Cholestasis (PFIC) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |